初始治疗-话题@MedSci

#初始治疗#

37篇内容 | 1720人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2022129, encodeId=c1c42022129fb, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=ARD：RA患者初始治疗使用糖皮质激素后停药成功率如何？, objectType=article, longId=732070, objectId=b09de32070b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b09de32070b1, replyNumber=0, likeNumber=102, createdTime=2023-06-21, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b09de32070b1, moduleTitle=ARD：RA患者初始治疗使用糖皮质激素后停药成功率如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b09de32070b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022128, encodeId=11ec2022128d2, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标, objectType=article, longId=299284, objectId=0f55299284f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f55299284f7, replyNumber=0, likeNumber=85, createdTime=2022-06-15, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f55299284f7, moduleTitle=Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f55299284f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022127, encodeId=5928202212eec, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=105, createdTime=2022-07-27, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022125, encodeId=ed0c202212509, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=AJRCCM：肺动脉高压初始治疗策略与长期生存的关系, objectType=article, longId=218014, objectId=09bf218014d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09bf218014d3, replyNumber=0, likeNumber=78, createdTime=2021-12-19, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09bf218014d3, moduleTitle=AJRCCM：肺动脉高压初始治疗策略与长期生存的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09bf218014d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022126, encodeId=c1b02022126b8, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=JACC：肺动脉高压患者，初始治疗选择三联还是二联药物治疗？, objectType=article, longId=218277, objectId=55ae2182e7a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55ae2182e7a8, replyNumber=0, likeNumber=97, createdTime=2022-08-15, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55ae2182e7a8, moduleTitle=JACC：肺动脉高压患者，初始治疗选择三联还是二联药物治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55ae2182e7a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022124, encodeId=414a20221244c, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=pevonedistat联合阿扎胞苷作为治疗罕见骨髓癌的初始治疗试验宣告失败, objectType=article, longId=217085, objectId=f61e21e085ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f61e21e085ca, replyNumber=0, likeNumber=94, createdTime=2021-11-08, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f61e21e085ca, moduleTitle=pevonedistat联合阿扎胞苷作为治疗罕见骨髓癌的初始治疗试验宣告失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f61e21e085ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022123, encodeId=119b2022123c5, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=JAMA Netw Open：晚期口咽鳞状细胞癌的更佳初始治疗方案？, objectType=article, longId=212280, objectId=7c662122804b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c662122804b, replyNumber=0, likeNumber=95, createdTime=2021-09-19, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c662122804b, moduleTitle=JAMA Netw Open：晚期口咽鳞状细胞癌的更佳初始治疗方案？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c662122804b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022122, encodeId=ffed20221229f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=NEJM：低温消融或药物治疗用于房颤的初始治疗, objectType=article, longId=206347, objectId=893920634e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=893920634e7a, replyNumber=0, likeNumber=93, createdTime=2021-04-01, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=893920634e7a, moduleTitle=NEJM：低温消融或药物治疗用于房颤的初始治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=893920634e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022121, encodeId=6c402022121ea, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Blood：早期CLL患者初始治疗的预测模型, objectType=article, longId=192536, objectId=1f9c19253679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9c19253679, replyNumber=0, likeNumber=109, createdTime=2020-07-10, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9c19253679, moduleTitle=Blood：早期CLL患者初始治疗的预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f9c19253679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022119, encodeId=7be7202211958, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Ann Rheum Dis：TNFi初始治疗中轴型脊柱关节炎患者的治疗反应和药物保留率, objectType=article, longId=178121, objectId=60d91e8121fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60d91e8121fe, replyNumber=0, likeNumber=83, createdTime=2019-09-14, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60d91e8121fe, moduleTitle=Ann Rheum Dis：TNFi初始治疗中轴型脊柱关节炎患者的治疗反应和药物保留率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60d91e8121fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022120, encodeId=b2572022120ef, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Chest：脓毒症初始治疗期间的输液量应该多还是少？, objectType=article, longId=186700, objectId=f5ef186e00bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5ef186e00bb, replyNumber=0, likeNumber=76, createdTime=2020-04-22, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5ef186e00bb, moduleTitle=Chest：脓毒症初始治疗期间的输液量应该多还是少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5ef186e00bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022117, encodeId=5bcf202211e08, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, objectType=article, longId=154370, objectId=61761543e050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61761543e050, replyNumber=0, likeNumber=79, createdTime=2019-06-17, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61761543e050, moduleTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61761543e050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022116, encodeId=79c820221168d, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Blood：来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗，缓解率高且持久, objectType=article, longId=148333, objectId=c82614833341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c82614833341, replyNumber=0, likeNumber=76, createdTime=2018-12-20, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c82614833341, moduleTitle=Blood：来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗，缓解率高且持久, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c82614833341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022118, encodeId=604f20221181e, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Lancet Respir Med：初始治疗血液嗜酸性粒细胞性COPD：LABA-ICS vs LAMA, objectType=article, longId=154646, objectId=5b4e15464637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4e15464637, replyNumber=0, likeNumber=79, createdTime=2019-03-25, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4e15464637, moduleTitle=Lancet Respir Med：初始治疗血液嗜酸性粒细胞性COPD：LABA-ICS vs LAMA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4e15464637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022112, encodeId=43cb2022112e3, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=《中国多发性骨髓瘤诊治指南(2017年修订)》初始治疗部分的解读, objectType=article, longId=121210, objectId=b03612121068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b03612121068, replyNumber=0, likeNumber=68, createdTime=2018-08-11, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b03612121068, moduleTitle=《中国多发性骨髓瘤诊治指南(2017年修订)》初始治疗部分的解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b03612121068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022115, encodeId=5a2c2022115eb, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=J Gen Intern Med：2型糖尿病合并CKD患者初始治疗：二甲双胍vs磺脲类, objectType=article, longId=135662, objectId=5f6e135662bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f6e135662bb, replyNumber=0, likeNumber=84, createdTime=2018-12-12, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f6e135662bb, moduleTitle=J Gen Intern Med：2型糖尿病合并CKD患者初始治疗：二甲双胍vs磺脲类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f6e135662bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022111, encodeId=67ee2022111a2, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Rheumatology (Oxford)：初始治疗是否影响低疾病活动性RA患者10年后结局？, objectType=article, longId=120566, objectId=75c412056621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75c412056621, replyNumber=0, likeNumber=81, createdTime=2018-08-22, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75c412056621, moduleTitle=Rheumatology (Oxford)：初始治疗是否影响低疾病活动性RA患者10年后结局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75c412056621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022105, encodeId=da5f202210576, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Circulation：CHARON研究：他汀早期初始治疗或能使HeFH儿童获益, objectType=article, longId=110803, objectId=851111080338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=851111080338, replyNumber=0, likeNumber=80, createdTime=2017-10-23, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=851111080338, moduleTitle=Circulation：CHARON研究：他汀早期初始治疗或能使HeFH儿童获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=851111080338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022106, encodeId=5cc320221061f, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=Eur Urol：不同初始治疗方案对局限性前列腺癌患者的长期心理和生活质量影响。, objectType=article, longId=111165, objectId=160d1111650e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=160d1111650e, replyNumber=0, likeNumber=84, createdTime=2018-04-19, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=160d1111650e, moduleTitle=Eur Urol：不同初始治疗方案对局限性前列腺癌患者的长期心理和生活质量影响。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=160d1111650e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2022109, encodeId=8f2f2022109c9, content=<a href='/topic/show?id=0ca732196ef' target=_blank style='color:#2F92EE;'>#初始治疗#</a>, objectTitle=【WCLC 2017】周彩存教授&吴凤英教授：阿帕替尼在晚期非鳞NSCLC初始治疗进展后持续使用仍然有效, objectType=article, longId=116890, objectId=3e7f116890ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e7f116890ab, replyNumber=0, likeNumber=77, createdTime=2018-09-06, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e7f116890ab, moduleTitle=【WCLC 2017】周彩存教授&吴凤英教授：阿帕替尼在晚期非鳞NSCLC初始治疗进展后持续使用仍然有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e7f116890ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

初始治疗

2020-05-29

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

ARD：RA患者初始治疗使用糖皮质激素后停药成功率如何？

2023-06-21

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Liver Cancer：Lenvatinib(仑伐替尼)初始治疗出现应答是仑伐替尼（LEN)+经动脉化疗栓塞(LEN-TACE)序贯治疗的预后指标

2022-06-15

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-07-27

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

AJRCCM：肺动脉高压初始治疗策略与长期生存的关系

2021-12-19

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

JACC：肺动脉高压患者，初始治疗选择三联还是二联药物治疗？

2022-08-15

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

pevonedistat联合阿扎胞苷作为治疗罕见骨髓癌的初始治疗试验宣告失败

2021-11-08

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

JAMA Netw Open：晚期口咽鳞状细胞癌的更佳初始治疗方案？

2021-09-19

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

NEJM：低温消融或药物治疗用于房颤的初始治疗

2021-04-01

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Blood：早期CLL患者初始治疗的预测模型

2020-07-10

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Ann Rheum Dis：TNFi初始治疗中轴型脊柱关节炎患者的治疗反应和药物保留率

2019-09-14

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Chest：脓毒症初始治疗期间的输液量应该多还是少？

2020-04-22

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效

2019-06-17

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Blood：来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗，缓解率高且持久

2018-12-20

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Lancet Respir Med：初始治疗血液嗜酸性粒细胞性COPD：LABA-ICS vs LAMA

2019-03-25

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

《中国多发性骨髓瘤诊治指南(2017年修订)》初始治疗部分的解读

2018-08-11

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

J Gen Intern Med：2型糖尿病合并CKD患者初始治疗：二甲双胍vs磺脲类

2018-12-12

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Rheumatology (Oxford)：初始治疗是否影响低疾病活动性RA患者10年后结局？

2018-08-22

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Circulation：CHARON研究：他汀早期初始治疗或能使HeFH儿童获益

2017-10-23

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

Eur Urol：不同初始治疗方案对局限性前列腺癌患者的长期心理和生活质量影响。

2018-04-19

ms4468361851264128 (审核中...)

前往app查看评论内容

#初始治疗#

【WCLC 2017】周彩存教授&吴凤英教授：阿帕替尼在晚期非鳞NSCLC初始治疗进展后持续使用仍然有效

2018-09-06

科室
- - 订阅+
  - 更多科室
工具
服务